Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Immunodeficient mice are increasingly used to assay human hematopoietic repopulating cells as well as leukemia-initiating cells. One method commonly used to isolate these rare cells is to sort cells stained with fluorochrome-conjugated antibodies into fractions, then transplant the different fractions into immunodeficient mice to test their repopulating ability. The antibodies are generally treated as being neutral in terms of their effects on the experiment. Human repopulating cells are thought to express CD34 and lack CD38. Here we present evidence that anti-CD38 antibodies have a profound inhibitory effect on engraftment of cord blood and leukemia cells. We show that this effect is Fc-mediated and can be overcome by treating mice with immunosuppressive antibodies. When this inhibitory effect is prevented, we demonstrate that the CD34+CD38+ fraction of certain acute myeloid leukemia samples contains all, or at least most, leukemia-initiating cell capacity. This study highlights the potential pitfall of antibody-mediated clearance of repopulating cells and is important for any groups working with this model. More importantly, the work suggests that there is greater variation in the phenotypes of leukemia-initiating cells than previously suggested.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AML leukemia initiating cells frequently have surface-phenotype features of lineage-commitment (CD34+38+, CLL-1+, CD71+, CD90−, c-Kit-)(42–52).”
From CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors (2012) · cites this paper as [42]
Citations
Cites
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
Self-citationMulti-Organ, Multi-Lineage Engraftment by a Single Bone Marrow-Derived Stem Cell
Krause, D. S., Theise, N. D., Collector, M. I., Henegariu, O., Hwang, S., Gardner, R., Neutzel, S., & Sharkis, S. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00328-2 · Cited by 2,667
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Multiple defects in innate and adaptive immunologic function in NOD/LtSz- scid mice.
Shultz, L. D., Schweitzer, P. A., Christianson, S. W., Gott, B., Schweitzer, I. B., Tennent, B., McKenna, S., Mobraaten, L., Rajan, T. V., Greiner, D. L., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.180 · Cited by 1,223
Hope, K. J., Jin, L., & Dick, J. E. (2004) · Nature Immunology · doi:10.1038/ni1080 · Cited by 968
Ishikawa, F., Yoshida, S., Saito, Y., Hijikata, A., Kitamura, H., Tanaka, S., Nakamura, R., Tanaka, T., Tomiyama, H., Saito, N., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1350 · Cited by 909
Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice
Bhatia, M., Wang, J. C. Y., Kapp, U., Bonnet, D., & Dick, J. E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5320 · Cited by 850 · cited 2×
“There are 2 caveats that may explain why CD34 CD38 cells did not engraft: (1) We assessed engraftment of sorted fractions at 8 to 11 weeks and had no leukemia engraftment from 4 of 7 leukemia samples injected with CD34 CD38 cells; it is possible that CD34 CD38 cells may initiate leukemia only at later time points or o…”
BackgroundMethodSelf-citationJordan, C., Upchurch, D., Szilvassy, S., Guzman, M., Howard, D., Pettigrew, A., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401903 · Cited by 821
Cozzio, A., Passegué, E., Ayton, P. M., Karsunky, H., Cleary, M. L., & Weissman, I. L. (2003) · Genes & Development · doi:10.1101/gad.1143403 · Cited by 663
Kojouri, K., Vesely, S. K., Terrell, D. R., & George, J. N. (2004) · Blood · doi:10.1182/blood-2004-03-1168 · Cited by 653
Cited by
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446
Evolution of the Cancer Stem Cell Model
Kreso, A., & Dick, J. E. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.006 · Cited by 2,224
“Cg-Prkdcscid Il2rgtm1Wjl /SzJ (NSG) mice, L-IC can now be detected in other fractions (Taussig et al., 2008).”
BackgroundData-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303
“Subsequent studies have demonstrated that both CD38 (Taussig et al., 2008) and CD34 (Taussig et al.”
InfluentialCancer Stem Cells: Current Status and Evolving Complexities
Visvader, J. E., & Lindeman, G. J. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.05.007 · Cited by 1,287
“In patients with del(5q) myelodysplastic syndrome, rare stem cells were found to be refractory to therapeutic targeting in individuals in remission, which probably accounts for relapse (Tehranchi et al., 2010).”
BackgroundCancer stem cells: an evolving concept
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3184 · Cited by 1,171
“However, the reproducibility of these findings remains controversia”
Background
Metadata
- Authors
- Taussig, D. C., Miraki-Moud, F., Anjos-Afonso, F., Pearce, D. J., Allen, K., Ridler, C., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S. G., Lister, T. A., Gribben, J. G., & Bonnet, D.
- Affiliations
- St Bartholomew's Hospital (GB)
- Department of Medical Oncology, St Bartholomew's Hospital, London; and
- Haematopoietic Stem Cell Laboratory and
- Cancer Research UK (GB)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-08-01
- Volume
- 112
- Issue
- 3
- Pages
- 568-575
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1988397531
- Cited by
- 373
- References
- 25
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 11 · 2023: 14 · 2022: 12 · 2021: 14 · 2020: 19 · 2019: 16 · 2018: 12 · 2017: 20 · 2016: 21 · 2015: 29 · 2014: 28 · 2013: 34 · 2012: 42
- FWCI
- 20.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- anti-CD38 monoclonal antibody, leukemia-initiating cells, CD34, CD38, acute myeloid leukemia, immunodeficient mice, cellular heterogeneity
- MeSH terms
- Animals, Antibodies, Cells, Cultured, Fetal Blood, Graft Survival, Humans, Neoplasm Transplantation, Leukemia, Myeloid, Acute, Mice, SCID, Antigens, CD34, Cord Blood Stem Cell Transplantation, Mice, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. https://app.cochat.ai/papers/10.1182/blood-2007-10-118331
- The paper
- Taussig, D. C., Miraki-Moud, F., Anjos-Afonso, F., Pearce, D. J., Allen, K., Ridler, C., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S. G., Lister, T. A., Gribben, J. G., & Bonnet, D. (2008). Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. https://doi.org/10.1182/blood-2007-10-118331
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.